Form 4: Amylyx Pharmaceuticals CFO James M. Frates Reports Stock and Option Transactions

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, reports acquisition of restricted stock units and stock options, along with adjustments to beneficial ownership.

Summary

• James M. Frates, CFO of Amylyx Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 6, 2025, Frates acquired 68,420 shares of common stock through a restricted stock unit (RSU) award.
• These RSUs vest in four equal annual installments starting March 1, 2026, contingent upon continued service.
• Frates also acquired options to purchase 102,630 shares of common stock at an exercise price of $3.61, vesting over 48 months starting March 1, 2026.
• The report also indicates adjustments to shares held indirectly through trusts, with Frates disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option transactions. The vesting schedules suggest a long-term commitment from the CFO.

Positives

• The acquisition of RSUs and stock options suggests confidence in the company's future performance by a key executive.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Equity compensation in the form of RSUs and stock options is a common practice among publicly traded pharmaceutical companies to align management's interests with those of shareholders.
• Vesting schedules, such as the four-year vesting period for the RSUs and the 48-month vesting for the options, are standard in the industry to incentivize long-term commitment.
• Companies like Biogen, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals also utilize similar equity compensation structures for their executives.

Stakeholder Impact

• Shareholders may view the equity grants as an incentive for management to drive long-term value.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates